English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

TO THE EDITOR—We read with interest the recent article by Thibault et al [1], which described laboratory analyses of injection equipment collected from people who inject drugs in France. In particular, the detection of hepatitis C virus (HCV) RNA in 80% of pooled samples of alcohol and cotton swabs raises concerns about the possible role of swabs in HCV transmission. While the accompanying editorial notes that " [c]onfirming these results with epide-miologic studies may take time " [2p1820], we present early epidemiological data on this relationship. Between 1999 and 2002, we conducted a longitudinal study of anti-HCV– negative people who inject drugs in 3 sites in New South Wales, Australia [3– 5]. A total of 68 incident cases of HCV infection were observed (30.8 cases/100 person-years; 95% confidence interval [CI], 24.3–39.0). Independent predictors of seroconversion were injection history of <1 year (adjusted hazard ratio [HR], The baseline prevalence of swab sharing (defined as " wiping your injection site with a swab previously used to wipe another person's injection site in the last 6 months ") was 6%. In contrast to receptive syringe sharing (unadjusted swabs was not associated with HCV ser-oconversion (unadjusted HR, 0.68; 95% CI, .21–2.15). As suggested in the accompanying editorial [2], ideally the association between swab sharing and HCV seroconversion should be studied in cohorts with a low prevalence of receptive syringe and container sharing and at least a modest amount of swab sharing. Despite being conducted in a setting of high harm reduction coverage including needle and syringe programs and opioid substitution treatment [6], our cohort had both high prevalence of receptive syringe sharing (27% in the previous 6 months) and container (ie, spoon) sharing (25%), relative to swab sharing (6%) at baseline. While the prevalence of swab sharing was low in our cohort and we were unable to detect a statistically significant relationship between this behavior and incident HCV infection, it would appear prudent to continue to emphasize avoidance of swab reuse in this population. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.

Hepatitis C Virus Transmission in People Who Inject Drugs: Swabs May Not Be the Main Culprit